Radiopharmaceutical developer Resolution Pharmaceuticals has closeda private placement offering that brings in $7.3 million to theMississauga, Ontario, firm. The placement was made to a groupof investors that includes Working Ventures Canadian Fund
Radiopharmaceutical developer Resolution Pharmaceuticals has closeda private placement offering that brings in $7.3 million to theMississauga, Ontario, firm. The placement was made to a groupof investors that includes Working Ventures Canadian Fund andTriax Growth Fund.
Resolution will use the funds to accelerate development ofRP128, a peptide-based agent for imaging acute and chronic inflammation.Resolution was founded by Nordion International and Allelix Biopharmaceuticals,and those firms will retain large equity stakes in Resolution,according to the company.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.